Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Q2 2026
EPS
-$1.14
est -$1.18
+3.7%
Revenue
$25M
est $15M
+68.9%
Vertex's $85.00 per share all-cash deal, expected to close this quarter, now looks locked in as PALSONIFY's net product revenue more than doubled to $24.0 million. Guidance is withdrawn and there is no earnings call, so the merger vote is the only catalyst left.